Results 101 to 110 of about 80,480 (249)

BLINATUMOMAB IN THE THERAPY OF ACUTE B-LYMPHOID LEUKEMIA

Mediterranean Journal of Hematology and Infectious Diseases
Blinatumomab, a CD19-CD3 bispecific T cell engager (BiTE), has two recombinant single-chain variable fragments that temporarily link CD3+ T cells and CD19+ B cells, leading to the T cell-mediated lysis of neoplastic B cells.
Ugo Testa, Elvira Pelosi, Germana Castelli, Patrizia Chiusolo   +3 more
doaj   +1 more source

Ph‐Negative Acute Lymphoblastic Leukemia in the Older Adults: Biology, Therapeutic Strategies and Unmet Needs

European Journal of Haematology, Volume 117, Issue 1, Page 24-41, July 2026.
ABSTRACT Acute lymphoblastic leukaemia (ALL) in older adults represents a growing clinical challenge, driven by an ageing population, adverse disease biology, and reduced tolerance to intensive chemotherapy. Although pediatric‐inspired regimens have improved outcomes in younger adults with Philadelphia chromosome (Ph)‐negative ALL, survival in older ...
Antonella Bruzzese, Ernesto Vigna, Enrica Antonia Martino, Santino Caserta, Francesco Mendicino, Maria Eugenia Alvaro, Caterina Labanca, Eugenio Lucia, Virginia Olivito, Marco Fiorillo, Nicola Amodio, Fortunato Morabito, Massimo Gentile   +12 more
wiley   +1 more source

Liver Injury From Medications Used for Treating Inflammatory Bowel Disease: The Drug‐Induced Liver Injury Network Experience

Liver International, Volume 46, Issue 7, July 2026.
ABSTRACT Background We aimed to investigate and characterise DILI due to approved therapies for inflammatory bowel disease (IBD). Methods Using the Drug‐Induced Liver Injury Network (DILIN) prospective study, we evaluated definite, highly likely, or probable DILI attributed to IBD therapies, including use for non‐IBD indications (but excluding ...
Harish Gopalakrishna, Jiezhun Gu, Yi‐Ju Li, Huiman Barnhart, Dina Halegoua‐DeMarzio, Herbert L. Bonkovsky, A. Sidney Barritt, Jean P. Molleston, Naga P. Chalasani, Marwan Ghabril   +9 more
wiley   +1 more source

Chronic myeloid leukemia (CML): prognostic factors and survival analysis

São Paulo Medical Journal
The prognostic value of different factors upon diagnosis of CML was analysed in 45 Philadelphia (Ph1)-positive patients. The median survival was 48 months.
Gisele Wally Braga, Maria de Lourdes Lopes Ferrari Chauffaille, José Eduardo Cajado Moncau, Elizabeth Xisto Souto, Maria Regina Regis Silva, José Kerbauy   +5 more
doaj   +1 more source

MYCN Amplification in RB1‐Inactivated Retinoblastoma: Association With High‐Risk Features

Pediatric Blood &Cancer, Volume 73, Issue 6, June 2026.
ABSTRACT Background MYCN amplification occurs in a subset of retinoblastoma cases, both with and without RB1 inactivation. It has been suggested that retinoblastomas with MYCN amplification represent a distinct entity with more aggressive clinical behavior.
Kyriaki Papaioannou, Regina Kubica, Karen Fischhuber, Jasmin Beygo, Madlen Reschke, Petra Ritter‐Sovinz, Eva Biewald, Petra Ketteler, Dietmar Lohmann, Deniz Kanber   +9 more
wiley   +1 more source

A new complex variant Philadelphia chromosome, t(1;9;22)ins(17;22), characterized by fluorescence in situ hybridization in an adult ALL

, 1999
A new complex variant Philadelphia chromosome was detected in a 65-year-old man with acute, pre-B, lymphoblastic leukemia (ALL). The classic cytogenetic analysis identified an apparently balanced three-way translocation t(1;9;22)(q25;q34;q11.2 ...
Fan, Yao-Shan, Rizkalla, Kamilia, Barr, Robert M   +2 more
core   +1 more source

PARP inhibition and pharmacological ascorbate demonstrate synergy in castration‐resistant prostate cancer

Molecular Oncology, Volume 20, Issue 6, Page 1626-1642, June 2026.
Pharmacologic ascorbate (vitamin C) increases ROS, disrupts cellular metabolism, and induces DNA damage in CRPC cells. These effects sensitize tumors to PARP inhibition, producing synergistic growth suppression with olaparib in vitro and significantly delayed tumor progression in vivo. Pyruvate rescue confirms ROS‐dependent activity.
Nicolas Gordon, Peter T. Gallagher, Orly I. Richter, Neermala Poudel Neupane, Amy C. Mandigo, Jennifer J. McCann, Emanuela Dylgjeri, Irina Vasilevskaya, Christopher McNair, Channing J. Paller, Wm. Kevin Kelly, Karen E. Knudsen, Matthew J. Schiewer, Ayesha A. Shafi   +13 more
wiley   +1 more source

PB1891: VARIANT PHILADELPHIA CHROMOSOME IN CML

HemaSphere, 2022
N. Bouayed Abdelmoula, S. Aloulou, B. Abdelmoula   +2 more
doaj   +1 more source

Symptomatic mucocutaneous toxicity of hydroxyurea in Philadelphia chromosome-negative myeloproliferative neoplasms the mister hyde face of a safe drug

, 2012
The current study was conducted to evaluate severe mucocutaneous toxicity during treatment with hydroxyurea (HU) in a large cohort of patients with Philadelphia chromosome-negative myeloproliferative neoplasms (MPN)
Spadea, A, Pessina, G, Latagliata, R, Andriani, A, Porrini, R, Alimena, G, Annino, L, Trape, G, Anaclerico, B, Rago, A, Mazzucconi, Mg, Montanaro, M, Cotroneo, E, Cedrone, M, Majolino, I, Di Giandomenico, J, Breccia, M, Cimino, G., Felici, S, Villiva, N, Spirito, F, Volpicelli, P, Montefusco, E, De Muro, M, Ferretti, A, Abruzzese, E, Avvisati, G, LO COCO, FRANCESCO   +27 more
core   +1 more source

BMI‐1 modulation and trafficking during M phase in diffuse intrinsic pontine glioma

FEBS Open Bio, Volume 16, Issue 6, Page 1213-1221, June 2026.
The schematic illustrates BMI‐1 phosphorylation during M phase, which triggers its translocation from the nucleus to the cytoplasm. In cycling cells, BMI‐1 functions within the PRC1 complex to mediate H2A K119 monoubiquitination. Following PTC596‐induced M phase arrest, phosphorylated BMI‐1 dissociates from PRC1 and is exported to the cytoplasm via its
Banlanjo Umaru, Deepak Kumar Mishra, Shiva Senthil Kumar, Hao‐Han Pang, Brendan Devine, Komal Khan, Rachid Drissi   +6 more
wiley   +1 more source